Sam Williams

Sam is a Managing Partner, Life Sciences at IP Group plc.

He has 20 years’ experience in the biotechnology industry, both as a top-ranked equity analyst in the City and, subsequently, as an entrepreneur and chief executive. He is CEO of Istesso Limited, an IP Group backed drug discovery company, oversees IP Group’s biotechnology portfolio, and sits on the Group’s Executive Committee.

He is Chairman and/or non-executive director of the IP Group portfolio companies Autifony Therapeutics Ltd, Diurnal Group plc, Glythera Ltd and Microbiotica Ltd, as well as being Non-Executive Chairman of C4X Discovery Holdings plc.

Sam holds a PhD in molecular biology from Cambridge and a degree in biology from Oxford.